GSK's investigational vaccine 692342

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Tuberculosis

Phase 2

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

CompletedNCT00950612

GlaxoSmithKlineTuberculosis

Start: 2009-12-08End: 2010-09-30Updated: 2018-08-17

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

CompletedNCT01098474

GlaxoSmithKlineTuberculosis

Start: 2010-07-07End: 2012-03-16Updated: 2019-06-27

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults

CompletedNCT01262976

GlaxoSmithKlineTuberculosis

Start: 2011-01-17End: 2015-06-04Updated: 2018-09-17

Related Papers

Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults

Medicine2018-11-0146 citations

A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults

Medicine2016-01-0160 citations

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

2015-06-1099 citations

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.

2014-08-0942 citations